Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 11—November 2025
Synopsis
Trichosporon austroamericanum Infections among Hospitalized Patients, France, 2022–2024
Table 2
Antifungal susceptibility testing of isolates from investigation of Trichosporon austroamericanum infections among hospitalized patients, France, 2022–2024*
| Strain no. | MIC per antifungal agent, µg/mL |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| AMB | 5-FC | FCZ | ITC | VRC | POS | CAS | MCF | AND | |
| L0221 | 1 | 64 | 0.5 | 0.12 | 0.03 | 0.12 | 8 | 8 | 8 |
| L0385 | 0.25 | 32 | 0.5 | 0.06 | 0.015 | 0.06 | >8 | >8 | >8 |
| L0399 | 0.25 | 16 | 1 | 0.06 | 0.015 | 0.12 | >8 | >8 | >8 |
| L0419 | 0.12 | >64 | 1 | 0.06 | 0.015 | 0.06 | >8 | >8 | >8 |
| L0445 | 2 | >64 | 1 | 0.12 | 0.03 | 0.25 | >8 | >8 | >8 |
| L0458 | 0.5 | 32 | 1 | 0.12 | 0.03 | 0.12 | 8 | 8 | 8 |
*AMB, amphotericin B; ANI, anidulafungin; CAS, caspofungin; FCZ, fluconazole; ITC, itraconazole; MIF, micafungin; VRC, voriconazole; POS, posaconazole; 5-FC, 5-Fluorocytosine.
Page created: September 18, 2025
Page updated: November 20, 2025
Page reviewed: November 20, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.